| Texto completo | |
| Autor(es): Mostrar menos - |
Silva-Santos, Yasmin
;
Pagni, Roberta Liberato
;
Gamon, Thais Helena Martins
;
de Azevedo, Marcela Santiago Pacheco
;
Bielavsky, Monica
;
Darido, Maria Laura Goussain
;
de Oliveira, Danielle Bruna Leal
;
de Souza, Edmarcia Elisa
;
Wrenger, Carsten
;
Durigon, Edson Luiz
;
Luvizotto, Maria Cecilia Rui
;
Ackerman, Hans Christian
;
Marinho, Claudio Romero Farias
;
Epiphanio, Sabrina
;
Carvalho, Leonardo Jose Moura
Número total de Autores: 15
|
| Tipo de documento: | Artigo Científico |
| Fonte: | FRONTIERS IN PHARMACOLOGY; v. 15, p. 14-pg., 2024-07-12. |
| Resumo | |
COVID-19 causes more severe and frequently fatal disease in patients with pre-existing comorbidities such as hypertension and heart disease. SARS-CoV-2 virus enters host cells through the angiotensin-converting enzyme 2 (ACE2), which is fundamental in maintaining arterial pressure through the renin-angiotensin system (RAS). Hypertensive patients commonly use medications such as angiotensin-converting enzyme inhibitors (ACEi), which can modulate the expression of ACE2 and, therefore, potentially impact the susceptibility and severity of SARS-CoV-2 infection. Here we assessed whether treatment of ACE2-humanized (K18-hACE2) mice with the ACEi Lisinopril affects lung ACE2 levels and the outcome of experimental COVID-19. K18-hACE2 mice were treated for 21 days with Lisinopril 10 mg/kg and were then infected with 105 PFU of SARS-CoV-2 (Wuhan strain). Body weight, clinical score, respiratory function, survival, lung ACE2 levels, viral load, lung histology, and cytokine (IL-6, IL-33, and TNF-alpha) levels were assessed. Mice treated with Lisinopril for 21 days showed increased levels of ACE2 in the lungs. Infection with SARS-CoV-2 led to massive decrease in lung ACE2 levels at 3 days post-infection (dpi) in treated and untreated animals, but Lisinopril-treated mice showed a fast recovery (5dpi) of ACE2 levels. Higher ACE2 levels in Lisinopril-treated mice led to remarkably higher lung viral loads at 3 and 6/7dpi. Lisinopril-treated mice showed decreased levels of the pro-inflammatory cytokines IL-6 and TNF-alpha in the serum and lungs at 6/7dpi. Marginal improvements in body weight, clinical score and survival were observed in Lisinopril-treated mice. No differences between treated and untreated infected mice were observed in respiratory function and lung histology. Lisinopril treatment showed both deleterious (higher viral loads) and beneficial (anti-inflammatory and probably anti-constrictory and anti-coagulant) effects in experimental COVID-19. These effects seem to compensate each other, resulting in marginal beneficial effects in terms of outcome for Lisinopril-treated animals. (AU) | |
| Processo FAPESP: | 20/06409-1 - Avaliação da resposta imune humoral e da resposta inflamatória em pacientes com diagnóstico confirmado de COVID-19 no Hospital Sírio Libanês e correlação com a severidade da doença |
| Beneficiário: | Edison Luiz Durigon |
| Modalidade de apoio: | Auxílio à Pesquisa - Regular |
| Processo FAPESP: | 15/26722-8 - Drug discovery contra doenças infecciosas humanos |
| Beneficiário: | Carsten Wrenger |
| Modalidade de apoio: | Auxílio à Pesquisa - Temático |
| Processo FAPESP: | 23/05478-8 - A regulação da Septina 9 na Síndrome do Desconforto Respiratório Agudo associada à Malária: da citoadesão ao aumento da permeabilidade vascular |
| Beneficiário: | Sabrina Epiphanio |
| Modalidade de apoio: | Auxílio à Pesquisa - Regular |
| Processo FAPESP: | 20/06747-4 - Estudo da resposta imune humoral nas infecções recorrentes por Plasmodium vivax em gestantes da região amazônica |
| Beneficiário: | Cláudio Romero Farias Marinho |
| Modalidade de apoio: | Auxílio à Pesquisa - Regular |
| Processo FAPESP: | 22/13150-0 - Inflamação induzida por Malária: uma nova via para doenças cardiovasculares |
| Beneficiário: | Cláudio Romero Farias Marinho |
| Modalidade de apoio: | Auxílio à Pesquisa - Regular |
| Processo FAPESP: | 20/12277-0 - Drug discovery contra doenças infecciosas humanas |
| Beneficiário: | Edmarcia Elisa de Souza |
| Modalidade de apoio: | Bolsas no Brasil - Pós-Doutorado |